financetom
Business
financetom
/
Business
/
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing
May 29, 2024 1:31 PM

04:12 PM EDT, 05/29/2024 (MT Newswires) -- Michael S Brown, Director, on May 28, 2024, sold 1,172 shares in Regeneron Pharmaceuticals ( REGN ) for $1,142,536. Following the Form 4 filing with the SEC, Brown has control over a total of 12,544 shares of the company, with 1,382 shares held directly and 11,162 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/872589/000110465924066045/xslF345X03/tm2414958-1_4seq1.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Clearway Energy Q3 net income rises to $60 mln
Clearway Energy Q3 net income rises to $60 mln
Nov 4, 2025
Overview * Clearway Energy ( CWEN/A ) Q3 net income rises to $60 mln, driven by lower tax expenses * Adjusted EBITDA for Q3 2025 increases to $385 mln, supported by growth investments * Company raised $50 mln through equity issuance program Outlook * Company narrows 2025 full-year CAFD guidance to $420 mln-$440 mln * Clearway Energy ( CWEN/A )...
Insurer AIG's Q3 adjusted EPS rises 77% on underwriting performance
Insurer AIG's Q3 adjusted EPS rises 77% on underwriting performance
Nov 4, 2025
Overview * AIG Q3 adjusted EPS up 77% yr/yr, driven by strong underwriting performance * Net premiums written fell 2% yr/yr, reflecting changes in reinsurance structures Outlook * AIG expects investments in Convex Group and Onex Corporation to be earnings, EPS, and ROE accretive * Company plans to leverage strong balance sheet for future growth * AIG confident in achieving...
Corvus Pharma Q3 net loss narrows; R&D expenses rise 
Corvus Pharma Q3 net loss narrows; R&D expenses rise 
Nov 4, 2025
Overview * Corvus Q3 net loss narrows to $10.2 mln from $40.2 mln in 2024 * R&D expenses rise to $8.5 mln in Q3 due to clinical trial costs * Corvus expects cash to fund operations into Q4 2026 Outlook * Corvus expects to initiate atopic dermatitis Phase 2 trial in early Q1 2026 * Company anticipates reporting Phase 1...
Accel Entertainment Q3 revenue beats estimates helped by growth in Illinois and Montana markets 
Accel Entertainment Q3 revenue beats estimates helped by growth in Illinois and Montana markets 
Nov 4, 2025
Overview * Accel Entertainment ( ACEL ) Q3 revenue grows 9.1%, beating analyst expectations * Adjusted EBITDA for Q3 beats consensus, reflecting operational efficiency * Company completes $900 mln credit facility, enhancing growth capital flexibility Outlook * Company sees opportunities from Fairmount Park ramp-up and Louisiana market expansion * Accel expects distributed gaming growth in new states and markets *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved